Loading
BP
Biocorp Production Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 21 Jul 2022.
Biocorp Production: what insiders have been doing
Biocorp Production belongs to the Healthcare & Pharma sector. Filings by its managers are published through AMF. The past year has been quiet: not a single insider filing for Biocorp Production. The previous disclosure was published on 20 September 2023.
Since 2021, the database holds 1 purchase and 2 sales by insiders of the company.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
Insider Decl.
6
Thresholds
n/a
Buy Volume
€75,022
1 ops. · all time
Sell Volume
€71M
2 ops. · all time
Financial data
· cache
Last declaration on 20 September 2023
Declarations6 total
6,000 shares@ €35.0013.8% of flowActionHors plateforme de négociationISIN FR00127880652023DD928247
7,450 shares@ €35.0017.1% of flowActionHors plateforme de négociationISIN FR00127880652023DD928474
30,000 shares@ €35.0069.0% of flowActionHors plateforme de négociationISIN FR00127880652023DD928248
1,998,800 shares@ €35.0099.9% of flowActionHors plateforme de négociationISIN FR00127880652023DD923415
3,000 shares@ €25.00720.1% of flowActionEuronext Growth ParisISIN FR00127880652022DD853011
Canonical exit: 17 Oct 2022 (T+90)
25,000 shares@ €28.90100.0% of flowActionHors plateforme de négociationISIN FR00127880652021DD735966
6 of 6 declarations
About Biocorp Production
BIOCORP PRODUCTION is a French company specializing in the design and manufacture of medical devices and innovative drug-delivery systems. Originally established in 2004 in Issoire, near Clermont-Ferrand, the company grew out of a family industrial background and built its business on a combination of precision plastics engineering, medical-device know-how, and connected technologies. BIOCORP emphasizes an integrated operating model, controlling the full value chain from research and development through production and final packaging, which supports product quality, customization, and faster innovation cycles.
The group first developed a portfolio of conventional drug-delivery devices and later expanded into connected solutions and smart accessories aimed at improving treatment adherence and patient experience. Its product range has included traditional delivery systems, connected injection systems, monitoring devices, and add-ons that can be adapted to existing injection pens on the market. This positioning has made BIOCORP a niche player in medical plastics and injectable drug-delivery technologies, with a focus on chronic diseases and on solutions that can integrate data collection and digital connectivity into everyday treatment routines.
Read moreShow less
From an industrial standpoint, BIOCORP operates two complementary French sites. The Clermont-Ferrand location hosts development, innovation, and support functions, while the Issoire site is dedicated to production and quality. The company states that it employs 105 people across these sites, underscoring a mid-sized, agile operating structure. This local manufacturing footprint in France is strategically important for quality control, supply-chain responsiveness, and the ability to move quickly from design to industrial scale-up, especially for medical-device customers requiring high reliability and regulatory discipline.
BIOCORP was listed on Alternext in July 2015 under ISIN FR0012788065. A key recent milestone was Novo Nordisk’s acquisition of a controlling stake, completed on August 4, 2023, after the Danish healthcare group bought 64.3% of BIOCORP’s share capital at EUR 35.00 per share. That transaction materially changed BIOCORP’s ownership profile and anchored the company within the ecosystem of one of the world’s leading diabetes-focused healthcare groups, which is highly relevant given BIOCORP’s expertise in injectable delivery devices and connected treatment solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
